Antibody Information
General Information of This Antibody
| Antibody ID | ANI0PKPQQ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Gatipotuzumab |
|||||
| Brand Name | PankoMab-GEX |
|||||
| Organization | NEMOD Biotherapeutics; Glycotope GmbH |
|||||
| Indication | Peritoneal cancer; Fallopian tube cancer; Ovarian cancer |
|||||
| Synonyms |
PankoMab-GEX; hPankoMab; PankoMab
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Undisclosed |
Antigen Info | ||||
| ChEMBI ID | ||||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTT
HYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEGLHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTT
HYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEGLHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GFPFSNYW
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
IRLKSNNYTT
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
TRHYYFDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLA
SGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLA
SGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
KSLLHSNGITY
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
QMS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
AQNLELPPT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
DS-3939 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (ECOG 0-1, LVEF ≥50%, measurable disease) must provide tumor samples for MUC1 analysis; exclusions include prior MUC1 therapy, active CNS metastases, uncontrolled infections (HIV/HBV/HCV), interstitial lung disease, or thromboembolic/autoimmune disorders within 6 months.
|
||||
| Administration Dosage |
One IV infusion Q3W on Day 1 of each 21-day cycle.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05875168 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study assesses dose-limiting toxicities (DLTs) within 3 months and tracks treatment-emergent adverse events (AEs) with objective response rates over ~31 months.
|
||||
| Other Endpoint |
Efficacy is evaluated via objective response rate, disease control rate, duration of response, and survival outcomes (PFS, OS) over ~31 months, alongside pharmacokinetic (AUC, Cmax, Tmax, T1/2) and immunogenicity (anti-drug antibodies) profiling extending up to 47 months, with TA-MUC1 expression analyzed at baseline.
|
||||